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Sequential multiple assignment randomized trials (SMARTs) are increasingly being used to inform clinical and
intervention science. In a SMART, each patient is repeatedly randomized over time. Each randomization occurs
at a critical decision point in the treatment course. These critical decision points often correspond to milestones in
the disease process or other changes in a patient’s health status. Thus, the timing and number of randomizations
may vary across patients and depend on evolving patient-specific information. This presents unique challenges
when analyzing data from a SMART in the presence of missing data. This paper presents the first comprehensive
discussion of missing data issues typical of SMART studies: we describe five specific challenges and propose a
flexible imputation strategy to facilitate valid statistical estimation and inference using incomplete data from a
SMART. To illustrate these contributions, we consider data from the Clinical Antipsychotic Trial of Intervention
and Effectiveness, one of the most well-known SMARTs to date. Copyright © 2014 John Wiley & Sons, Ltd.
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1. Introduction
Sequential multiple assignment randomized trials (SMARTs) [1–3] are increasingly being advocated
and used as a way to generate high quality data concerning the effects of sequences of treatments. In
a SMART, patients move through stages of treatment; they are randomized to an initial treatment at
study entry and then possibly re-randomized to additional treatments at subsequent treatment stages. An
important practical difficulty with analyzing clinical trial data, such as data collected in a SMART, is
missing data. The structure of missing data in a SMART can be complex because transition times and
randomization probabilities are outcome dependent. Contributions of this paper include identifying five
key challenges that are associated with missing data in SMARTs and developing a flexible imputation
strategy to facilitate valid estimation and inference.
Data collected in a SMART study can be used to estimate sequential individualized treatment strategies
known as dynamic treatment regimes [4], treatment polices [5], adaptive interventions [6], or adaptive
treatment strategies [7]. Precursors to SMARTs include the CALGB study 8923 for treating elderly
patients with primary acute myelogenous leukemia [8] and the STAR*D study for treatment of
depression [9–11]. Recent examples of SMARTs include trials for treating cancer at the
University of Texas MDAnderson Cancer Center [12], the ExTENd trial concerning alcohol dependence
at the University of Pennsylvania [13], and the Adaptive Interventions for Children with ADHD at SUNY
Buffalo [14] (see [15] for descriptions of more SMART studies). One of the most well-known sequential
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randomized trials is the Clinical Antipsychotic Trials of Intervention and Effectiveness (CATIE) study
for patients with schizophrenia [16]. The work presented in this paper is motivated by our involvement
with the CATIE study, which we use as a running illustrative example.
Dynamic treatment regimes formalize clinical decision-making as a sequence of decision rules,
one for each critical decision point, that map up-to-date patient information to a recommended treat-
ment [17–21]. The sequential and longitudinal nature of SMART studies, which facilitates estimation of
dynamic treatment regimes, also presents unique challenges for estimation and inference when data are
missing. There is a large body of work on accommodating missing data in nonsequential trials [22, and
references therein; 23]. Multiple imputation [22, 24, 25] has emerged as a popular method for dealing
with missing data because of its flexibility and general applicability. Multiple imputation has been
successfully applied in a wide range of domains including longitudinal data [26–29]. It is particularly
appealing in this context as it accommodates both item missingness and missingness because of study
attrition and is capable of preserving smoothness across longitudinal outcomes in the imputed data.
We propose a time-ordered nested conditional imputation strategy for use with SMART data. This
imputation strategy allows for longitudinal variables that are used in the clinical trial design, either in
dictating treatment randomization probabilities or determining the collection schedule of other variables.
In SMARTs, as in many longitudinal studies, study attrition accounts for much of the missing data, which
produces a nearly monotone pattern of missing data. We exploit this missing data pattern to ensure a
coherent multivariate predictive distribution exists, while retaining flexibility, scalability, and smoothness
across longitudinal outcomes.
The remainder of this paper is organized as follows. In Section 2, we identify five key challenges
to applying imputation methods to data collected from SMARTs and illustrate these challenges using
the CATIE study. In Section 3, we introduce a time-ordered nested conditional imputation strategy for
SMARTs. In Section 4, we apply this imputation methodology to the CATIE study. An analysis of the
CATIE data based on the imputations is presented in Section 5. We close with a discussion in Section 6.
2. Background
2.1. Missing data challenges arising in sequential multiple assignment randomized trial studies
There are at least five issues that present difficulties for building an effective imputationmodel for missing
data in SMARTs. Issue 1: The transition from one treatment stage to the next does not necessarily occur
at pre-specified times but instead is determined by a patient’s outcomes. Issue 2: Some outcome variables
are collected at the end of irregularly spaced stages, in replacement of, or in addition to, variables collected
during regularly scheduled study visits, resulting in irregular collection times for these variables. Issue
3: The observation of some variables may depend on patient covariate and outcome history, resulting in
structural missingness for a data-dependent portion of information on some of the participants. Issue 4:
Some individuals will be lost to follow-up prior to leaving a treatment stage, and thus, their end-of-stage
variables, along with regularly scheduled outcome variables, that would have been used to determine
the randomization probabilities for treatment assignment in remaining stages are missing. Issue 5: Some
individuals will be lost to follow-up prior to entering some treatment stages, and thus, treatments that
they would have been assigned in remaining stages are unknown.
2.2. The Clinical Antipsychotic Trial of Intervention and Effectiveness study
The CATIE study was an 18-month SMART that enrolled 1460 patients with schizophrenia.
Schizophrenia is a chronic disease characterized by abnormalities in a person’s perception of reality,
such as hallucinations, delusions, and confused speech and thought processes. Effective management
of schizophrenia requires sequential, individualized, adaption of treatment due to the chronic nature of
the disease, heterogenous treatment response, poor adherence, and/or intolerable side effects. As CATIE
is described in detail elsewhere [16, 30–33], we only give a simplified overview of the study, placing
emphasis on missing data.
There were two main randomized treatment stages in CATIE, which we term stages 1 and 2. In
CATIE, as in most SMARTs, two types of time-varying variables were collected: scheduled variables
and end-of-stage variables. Scheduled variables are collected at pre-specified collection times on all
individuals, for example, treatment adherence was measured monthly on all CATIE participants. End-
of-stage variables are specific to SMARTs and are collected only at the end of a treatment stage. An
example of an end-of-stage variable is the reason for discontinuing current treatment.
Copyright © 2014 John Wiley & Sons, Ltd. Statist. Med. 2014, 33 4202–4214
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Table I. Variables collected during Clinical Antipsychotic Trial of Intervention and Effectiveness utilized in
the imputation strategy and the months they were scheduled to be collected.
Variables with no missing information:
Time independent variables.
Age (cont), sex (dich), race (cat), tardive dyskinesia status at baseline (dich),
Marital status at baseline (dich), patient education (cat), hospitalization history in 3 months prior to CATIE (dich),
Clinical setting in which patient received CATIE treatment (cat), treatment prior to CATIE enrollment
(cat), stage 1 randomized treatment assignment (cat)
Variables with missing information:
Time independent variables:
Employment status at baseline (cat), years since first prescribed antipsychotic medication at baseline (cont),
Neurocognitive composite score at baseline (cont)
Variables recorded at all months 1–18 and at end-of-stage visits:
Adherence measured by the proportion of capsules taken since last visit (cont)
Variables recorded at months 0, 1, 3, 6, 9, 12, 15, 18, and at end-of-stage visits:
Body mass index (cont), clinical drug use scale (cat), clinical alcohol use scale (cat), clinical global
impressions of severity of illness score (cat), Positive and Negative Syndrome scale (cont), Calgary
Depression Score (cont), Simpson–Angus EP Mean scale (cont), Barnes Akathisia scale (cont), total
movement severity score (cont)
Variables recorded at months 0, 6, 12, 18 and at end-of-stage visits:
Quality of life total score (cont), SF-12 mental health summary (cont),
SF-12 physical health summary (cont), illicit drug use (dich)
Variables recorded only at end-of-stage visits:
Reason for discontinuing treatment (cat), stage 2 randomization arm (dich, when applicable), stage 2
treatment (cat, when applicable)
The type of the variable is indicated in parentheses; continuous variables are denoted with (cont), dichotomous variables
with (dich), and categorical with (cat).
CATIE, Clinical Antipsychotic Trial of Intervention and Effectiveness.
A large number of variables were collected at CATIE enrollment, for example, demographics and
disease history. Longitudinal scheduled variables, for example, symptom measurements, adherence, and
side effects, were planned to be collected either monthly, quarterly, or semi-annually (depending on
the variable). At an end-of-stage visit, the reason for discontinuing current treatment, as well as all
time-varying outcome variables, was collected regardless of the regular collection schedule. See Table I
for a partial list of variables and their collection schedules in CATIE.
At study entry, CATIE patients were randomized to one of five stage 1 treatments: olanzapine,
risperidone, quetiapine, ziprasidone, or perphenazine. At any monthly visit, a patient, in consultation
with his or her care provider, could decide to discontinue their current assigned treatment and enter the
next treatment stage (issues 1 and 2 in the preceding text). At any monthly visit in which a patient’s
current treatment was deemed adequate, only scheduled variables were collected (Table 1). Thus, no
end-of-stage variables were collected from CATIE participants who had adequate response to their stage
1 treatment for the entire CATIE trial (i.e., never transitioned into a later CATIE treatment stage; issue 3
in the preceding text).
Patients who transitioned into the second treatment stage were offered a choice of two randomization
arms, the tolerability arm or the efficacy arm. The tolerability arm was intended for individuals expe-
riencing intolerable side effects; in this arm, participants were randomized to olanzapine, risperidone,
quetiapine, or ziprasidone, excluding previous treatment. The efficacy arm was intended for participants
experiencing a lack of symptom control; in this arm, participants were randomized to either clozapine,
olanzapine, risperidone, or quetiapine, excluding previous treatment.‡
Study attrition was high in CATIE with only 705 of 1460 patients staying for the full 18 months. The
distribution of most baseline covariates appeared similar for participants that completed the CATIE study
and those that dropped out. However, individuals who completed the CATIE study were more likely to
‡We note that some participants experiencing a lack of efficacy chose to enter the tolerability arm to avoid being randomized
to clozapine, which is known to have severe side effects.
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be white, less likely to be treatment naive at baseline, and more likely to be abstinent from drugs and
alcohol (see Supporting information for full comparison.). Of the 705 participants who left the CATIE
study, 509 dropped out of the study before entering stage 2 (issue 4 and 5 in the preceding text). Dropout
is generally high in studies of antipsychotics for schizophrenia [34]. Additionally, in the CATIE study,
the primary outcome was time until all-cause treatment discontinuation, providing little incentive for
clinicians to keep nonadherent patients enrolled. Consequently, the majority of missing data (78.1%) was
due to study attrition, which produced a nearly monotone missing data pattern.
The trend in the amount of missing data over time and the proportion of missing data due to dropout
are similar for all scheduled time-varying variables collected during the CATIE study. We use three
variables to illustrate this pattern: Positive and Negative Syndrome scale (PANSS), body mass index
(BMI), and treatment adherence. The PANSS score is the standard medical scale for measuring symptom
severity in patients with schizophrenia with higher values corresponding to more symptoms [35]. Weight
gain, captured by BMI, is an important side effect associated with many antipsychotics that impacts a
patient’s overall health and their likelihood to adhere to treatment [36, 37]. Monitoring a patient’s treat-
ment adherence is important for optimal therapeutic benefit; adherence is measured using the proportion
of prescribed pills taken since the last visit. Figure 1 shows the proportion ofmissing data in PANSS, BMI,
and treatment adherence at scheduled visits. As illustrated here, most missing data are due to participant
dropout [22, 38].
3. Imputation methods
There are three types of missing data generating mechanisms: missing completely at random in which
the missing data pattern is independent of any variables, measured or unmeasured; missing at random
(MAR) in which the missing data pattern is dependent on observed variables; and not missing not at
random in which the missing data pattern depends on unobserved variables [22,39]. Imputation methods,
such as those described here, assume an MAR generating mechanism.
Generally, imputation models fall into one of two categories: fully conditional models wherein
a separate model is fit for each variable [40–42] or joint multivariate models wherein a single joint model
is fit to all variables [22, 25]. The data-dependent structural missingness inherent to SMART designs
makes specifying a single joint distribution difficult. For this reason, we opt for conditional imputation
models. However, we exploit the near-monotonicity and SMART-specific, sequential, structure of the
data to ensure a coherent multivariate joint distribution.
Let t = 0, 1,… , T denote the scheduled clinic visit times where t = 0 denotes baseline and t = T
denotes the end-of-study visit (see the succeeding text for details). At each time t, let 𝐯t,1,… , 𝐯t,Jt denote
the set of all covariates on all n trial participants that could potentially be collected on any participant at
time t. In general, the covariates potentially collected at time t need not be identical to those potentially
collected as some other time s ≠ t as collection schedules vary across variables.
In our implementation, the order 𝐯t,1,… , 𝐯t,Jt includes first the covariates, which, according to the
protocol, dictate when and if additional covariates should be collected, and second include variables,
Figure 1. Bar plots showing the amount of missing data in the CATIE study. The total height of the bar displays
the absolute number of people who have missing (a) Positive and negative syndrome scale, (b) body mass index,
and (c) adherence, as measured by pill count, at each of the monthly visits at which the scheduled variable was
collected. The dark grey area represents individuals with missing values because they have dropped out of the
study prior to that month. The unshaded area is the amount of item missingness in each variable.
Copyright © 2014 John Wiley & Sons, Ltd. Statist. Med. 2014, 33 4202–4214
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which are potentially missing by design. For example, in CATIE, an indicator of treatment discontin-
uation, would precede a variable coding reason for treatment discontinuation. The imputation models
used at each time point t are nested so that the model for 𝐯t,k depends only on 𝐯t,k−1,… , 𝐯1,1; this
sequential conditioning framework provides a straightforward approach for specifying a coherent mul-
tivariate distribution. An example dataset based on the CATIE study with the foregoing time-ordered
structure is provided in the Supporting information. In the succeeding text, we describe this time-order
conditional nested imputation modeling framework in general terms, before illustrating this approach
with the CATIE data.
3.1. Overview of time-ordered nested conditional imputation models
Fully conditional specification (FCS) imputation methods have been used to accommodate missing
data in a wide range of applications [43–53]. In general, FCS methods only require the specification
of conditional distributions for each variable and not a full joint distribution. When no restrictions are
placed on which variables are used as predictors in these conditional models, a number of theoretical and
practical issues can arise. For example, the existence of a joint multivariate distribution that is consistent
with all conditional distribution models is not guaranteed [38, 41, 54, 55], and convergence properties
are not yet known [41, 46]. Nonetheless, this approach appears to work well in practice, where miss-
ing data are imputed with a pseudo-Gibbs sampler, applying repeated iterations through the conditional
distribution models [41, 55].
Conditionally specified imputation models extend naturally to time-ordered data collected from
longitudinal clinical trials. For example, assuming all baseline variables are observed, these variables can
be used as predictors in an imputation model for missing data from the first follow-up visit. The imputed
and observed values from this first visit, in addition to the observed values from the baseline visit, can then
be used as predictors in an imputation model for missing information at the second follow-up visit and so
on. The predictors at earlier visits are a subset of predictors at later visits, creating a time-ordered nested
structure in the set of predictors used in the conditional imputation models. Thus, the set of potential
predictors used in imputation models increases with t.
Conditional models have been used to specify complex joint distributions in many areas [38, 54, 56].
Provided that at least some of the baseline variables are fully observed, a time-ordered nested condi-
tional imputation model avoids some of the problems associated with general FCS, for example, lack
of convergence or lack of joint multivariate distribution that is consistent with the conditional models.
The trade-off, in terms of model quality, is that one does not use future information, say at time t + h,
to impute data occurring at time t. But as long as the pattern of missing data is monotone or nearly mono-
tone, that is, if a participant is missing information at time t then all information at any time t + h is also
missing, then little is lost in terms of efficiency or bias.
We employ a Bayesian framework for generating values to impute missing information [57]. As
before, denote the vector of the jth variable collected at time t for all n trial participants by 𝐯t,j with
𝐯t,j, obs denoting the observed values and 𝐯t,j, miss denoting the missing information. Define t−1 ≡
𝐯0, 𝐯1,1,… 𝐯1,J1 ,… , 𝐯t−1,1,… , 𝐯t−1,Jt−1 .
Denote the conditional distribution of 𝐯t,j by f
(
𝐯t,j|t−1, 𝐯t,1,… , 𝐯t,j−1; 𝜃t,j), the prior distribution
of 𝜃t,j by 𝜋
(
𝜃t,j
)
, and the posterior distribution of 𝜃t,j by 𝜋
(
𝜃t,j|t−1, 𝐯t,1,… , 𝐯t,j−1, 𝐯t,j, obs, 𝜃1,1,… 𝜃t−1,Jt
… 𝜃t,j−1
)
. Then, assuming fully observed 𝐯0 for ease of notation, the resulting joint posterior predictive
distribution of the missing observations given the observed is
∫ · · ·∫
T∏
t=1
Jt∏
j=1
f
(
𝐯t,j
|||t−1, 𝐯t,1,… , 𝐯t,j−1; 𝜃t,j
)
𝜋
(
𝜃t,j
|||t−1, 𝐯t,1,… , 𝐯t,j−1, 𝐯t,j, obs, 𝜃1,1,… , 𝜃t−1,Jt ,… , 𝜃t,j−1
)
d𝜃t,j.
We sample from this distribution by first evaluating the posterior distribution 𝜋
(
𝜃1,1|𝐯0, 𝐯1,1, obs ), then
sampling a value of 𝜃∗1,1 to impute the missing values of 𝐯1,1 using f
(
𝐯1,1
|||0, 𝜃∗1,1
)
. We use these impu-
tations to estimate 𝜋
(
𝜃1,2
|||𝐯0, 𝐯1,1, 𝐯1,2, obs, 𝜃∗1,1
)
, again sampling a value 𝜃∗1,2 to impute missing values of
𝐯1,2 using f
(
𝐯1,2
|||0, 𝐯1,1, 𝜃∗1,2
)
. We continue until all posterior distributions have been estimated and all
missing values have been imputed. The foregoing process yields a single imputed dataset, whichwe repeat
to produce multiple complete datasets. Multiple imputation is recommended over a single imputation
because the uncertainty in the imputed values can be better accounted for in an analysis [22].
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This imputation strategy accommodates the missing data issues cataloged in Section 2.1. By first
imputing missing patient outcomes from early study visits, this information can be use to impute miss-
ing patient-specific transition times, end-of-stage variables, and treatment assignments at later stages.
Additionally, this time-ordered nested approach can be used to accommodate data-dependent structural
missingness by first imputing patient information needed to determine the collection timing and then
imputing nonstructurally missing values.
3.2. Specifying the conditional models
Because it considers separate models for each covariate, the general FCS framework has two important
strengths: scalability and flexibility. However, one potential drawback of specifying each univariate con-
ditional model separately at each time point is that smoothness in the mean (or variance) of longitudinal
outcomes is not imposed. In many situations, one can expect the time-varying mean of a longitudinal pro-
cess to be smooth. For example, in the CATIE study, one would expect that symptom severity and BMI
would exhibit such smoothness. We use a longitudinal Bayesian mixed effects model (BMEM) [58] to
impose smoothness on conditional imputation models for longitudinal variables when warranted.
To the best of our knowledge, a description of how to incorporate longitudinal imputation methods
that use time-varying predictors with missing information in the conditional specification framework is
lacking. In the succeeding text, we detail how to incorporate the BMEM into the proposed nested con-
ditionally specified framework. For clarity, we focus on a continuous outcome variable at time t denoted
by Rt (appropriate generalized linear BMEMs can be implemented for binary or categorical variables).
We construct a model for the distribution of Rt conditional on
{
R0,R1,… ,Rt−1
}
and all other vari-
ables at all times s ⩽ t. This conditional model is derived from a BMEM for
{
R0,R1,… ,Rt
}
using
random effects to model correlation between observations on the same individual and a spline (or sim-
ilar smooth function) to enforce smoothness over time on the conditional mean of
{
R0,R1,… ,Rt
}
.
Equation 1 provides an example BMEM with the subscript i denoting individual i:
Rs,i =
(
𝛾0 + gi
)
+ 𝛾⊤b 𝐯0,i + 𝛾
⊤𝐯s,i +
s∑
j=1
𝜈j(s − j)+ + 𝜖s,i for s ⩽ t (1)
The random intercept terms, gi, i = 1,… , n are assumed to be independent and normally distributed,
allowing individual outcomes to vary independently across trial participants. The error terms 𝜖s,i, i =
1,… , n, s = 1,… t, are also assumed to be normally distributed and independent across both trial partic-
ipants and study visits. In this example, a linear spline is used to model the smoothness in the expected
value of the longitudinal outcome, R over time, with the coefficients, 𝜈j, j = 1,… , t, constrained so that
Equation (1) is continuous in s ⩽ t. Note that the normally distributed error term and random effects terms
will define the covariance matrix for
{
R0,R1,… ,Rt
}
. The conditional distribution implied by this multi-
variate normal distribution defines our model for the distribution of Rt conditional on
{
R0,R1,… ,Rt−1
}
and all other variables at all times s ⩽ t. The Bayesian imputation model is estimated by defining priors
on the fixed-effects coefficients in Equation (1), and the variances of the Gaussian models the random
intercept and error terms are drawn from. Using this model, we sample from the posterior predictive
distribution to impute the missing values of Rt.
We construct a new BMEM at each time t, specify priors on the fixed-effects coefficients in
Equation (1), the variances of the random intercepts, and variances of the error terms. Then, if needed,
we use this model to impute missing values in Rt. This strategy borrows more information over time at
later time points for estimating imputation models than at earlier ones; Because of study attrition, this is
precisely when more information is needed. Evaluating a BMEM at an early time point using this strat-
egy will utilize information on many independent individuals (as little attrition has occurred) but fewer
time-varying observations on R for any one individual. Later time points will utilize information from
measurements on R over more time points because more longitudinal observations on the same individu-
als are used to evaluate the imputation models, but fewer independent observations (because of attrition)
are present at later time points.
Our use of the BMEM builds on the strengths of conditionally specified imputation models
(scalability and flexibility), while incorporating the advantage of using longitudinal imputation models
to borrow information over time. This imputation strategy is not restricted to imputing missing data col-
lected from a SMART and can be generalized to any longitudinal missing data problem. Because of the
Copyright © 2014 John Wiley & Sons, Ltd. Statist. Med. 2014, 33 4202–4214
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conditional nature of the trial design, the time-ordered conditional structure is especially powerful for
imputing missing information from a SMART.
4. Clinical Antipsychotic Trial of Intervention and Effectiveness schizophrenia trial
In Section 2.1, we described five characteristics of SMART studies that present challenges for imputation.
In Section 3, we proposed a time-ordered nested imputation strategy to meet these challenges. Here,
we illustrate the proposed strategy with data from the CATIE study. The primary motivation for using
imputation to accommodate missing data in CATIE is to perform a range of secondary analyses, including
estimation of an optimal dynamic treatment regime [17, 19], which we demonstrate in Section 5. The
primary outcome for the CATIE study was time until treatment discontinuation, but a large amount of
longitudinal information was collected on all participants, and several secondary outcomes are of clinical
interest. For clarity, PANSS will be the only variable imputed with a BMEM.
The multiple imputation methods we employ are essentially the same across time points; thus, we
describe the imputation procedure for a generic time point t. The imputation process is repeated to
generate 25 complete CATIE datasets. In some special cases, substantive and logical arguments can be
used to justify a single imputation for a missing variable, in these cases, the imputed value will be the
same across all completed datasets.
We first describe our imputation procedure for baseline variables. We then determine if, and when,
a participant who dropped out of CATIE should be imputed to transition into a subsequent treatment
stage. We then describe imputation models for end-of-stage variables and treatment assignment for these
later stages. Finally, we detail how to interweave the imputation of these transition times, treatment
assignments, end-of-stage variables, and scheduled variables within the time-ordered nested format. In
Section 4.6, we provide algorithm implementation details.
4.1. Imputing baseline variables
There are 11 baseline variables in CATIE with no missing data and 16 that contain some missing values;
a total of 3% of these baseline observations are missing. We use independent conditionally specified
models to impute the small amount of missing data at baseline, conditioning on the variables that were
fully observed (Table I). As this is standard, we omit a description.
4.2. Imputing stage transition times
We assume that had an individual who dropped out of CATIE instead remained in the study, he or she
would have elected to discontinue their current treatment at the month they were observed to dropout.
Hence, individuals who dropped out of CATIE at stage 1 are, at the month of dropout, singly imputed
to transition into the next treatment stage and thus receive a different treatment. The rationale for this
decision is that schizophrenia is a chronic disease requiring continuous treatment. Furthermore, because
treatment in CATIE is blinded, it is unlikely that an individual who drops out of CATIE will continue to
be treated with their assigned CATIE medication.
The single imputation for transition times in CATIE relies on an assumption informed by clinical
practice. In other settings, such an assumption may not be plausible, and an imputation model for the
transition time could be used. For example, one could impute a binary indicator of transition at each clinic
visit subsequent to patient dropout.
4.3. Imputing end-of-stage variables
Some end-of-stage information will also be singly imputed. When an individual chose to stop participat-
ing in CATIE while at a study visit, the CATIE protocol required clinicians to record the reason for this
early termination and collect all time-varying participant information, that is, the same information that
is recorded at an end-of-stage visit. Thus, we singly impute all end-of-stage information, including rea-
son for discontinuing treatment, with information collected at the participant’s exit visit when available.
Not all individuals had information collected before leaving the CATIE study; we multiply impute all
remaining missing end-of-stage information for these subjects.
With the exception of PANSS (Section 4.5), we utilize a univariate regression model for each end-
of-stage variable. The predictors in the univariate end-of-stage imputation models are baseline variables,
most recent treatment and scheduled time-varying variables, and the reason for discontinuing previous
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treatment. Because the distribution of end-of-stage variables for individuals who discontinue treatment
due to lack of therapeutic results will likely be different from that of individuals who discontinued
treatment due to intolerable side effects, we nest the most recent scheduled variables within reason for
discontinuing treatment in the imputation models. This allows the distribution of end-of-stage variables
to depend on reason for discontinuing treatment, while preserving computational tractability.
In CATIE, a small number of observed stage transitions occurred in any givenmonth. Consequently, we
pool the data within time-windows, months {1}, {2, 3}, {4, 5, 6}, {7, 8, 9}, {10, 11, 12}, {13, 14, 15}, and
{16, 17, 18}, to increase stability in estimating the parameters in the end-of-stage imputationmodels. That
is, data from individuals who transition into the next treatment stage within one time-window are used
to estimate imputation models for end-of-stage variables within that time-window. These time-windows
were chosen because most scheduled variables were collected at months 0, 1, 3, 6, 9, 12, 15, and 18.
4.4. Imputing new randomly assigned treatment
If an individual dropped out during stage 1, the choice of stage 2 randomization arm must be imputed.
Reason for discontinuing previous treatment was highly predictive of treatment arm choice; of the 99
individuals who were observed to enter the stage 2 efficacy arm, 75 (85.9%) gave ‘lack of therapeutic
effect’ as their primary reason for discontinuing treatment. Thus, our imputation model for the choice
of stage 2 randomization arm includes all baseline variables, previous treatment, reason for discon-
tinuing previous treatment, and all end-of-stage variables. After the randomization arm is multiply
imputed, assigned treatment is imputed using stage 2 treatment randomization probabilities defined in the
CATIE protocol.
4.5. Imputing additional missing time-varying information
As detailed in Table I, collection schedules differed for variables collected in CATIE. For each
scheduled variable collected at month t (except PANSS), we estimate a separate imputation model.
For example, treatment adherence was measured monthly; thus, separate imputation models were utilized
for each month. The imputation models for all scheduled variables (except PANSS) include as predictors
the following: baseline covariates, previous scheduled time-varying variables, current stage, and
randomized treatment. Appropriate conditional models were selected to suit the variable type (binary,
continuous, etc.).
Recall from the discussion in the beginning of Section 3 that at each month t the variables are
ordered; we put PANSS last in this ordering. Thus, the model for PANSS at month t can utilize all other
variables collected at month t. The nested structure described in Section 3.2 uses a series of longitudinal
mixed effect imputation models, one for each time point. For example, suppose we are imputing missing
values in PANSS at month t; the model uses the PANSS score at months 0, 1,… , t as the longitudinal
outcome and predictors: baseline covariates, currently assigned treatment, treatment stage, all time-
varying variables measured at the month of PANSS observation, and a spline on month of observation.
The spline included knots at monthly intervals, with spline coefficients constrained so themean of PANSS
was continuous in time. In our implementation, we include a random (participant specific) intercept to
model the correlation of PANSS scores measured on the same individual over time. We nest all time-
varying predictors within a binary indicator variable for if the PANSS measurement is a scheduled or
end-of-stage variable; if it is an end-of-stage variable, then the time-varying predictors are further nested
within reason for discontinuing previous treatment. It is worth emphasizing that we estimate a separate
PANSS BMEM imputation model at each time point PANSS was scheduled to be collected; each BMEM
includes observations for all time points up to the current one.
4.6. Algorithmic details for Clinical Antipsychotic Trial of Intervention and Effectiveness imputations
Here, we outline some algorithmic details for creating multiple complete datasets using data from
the CATIE study. There are many implementations for standard imputation methods [59–63]. We
implemented the methods described in Sections 4.2–4.5 using the R software packages mice [63] and
pan [62]. The former was used to estimate the univariate conditionally specified models, while the latter
to estimate a longitudinal BMEM for PANSS. In both mice and pan, imputed values are drawn from
the posterior predictive conditional distribution of the missing data given the selected predictors and the
observed values of the variable being imputed [57].
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The mice ‘norm’ argument was used for continuous variables (sometimes transformations were
applied prior to imputing); this assumes a Gaussian conditional distribution. To form conditional
models for binary and categorical variables, we used the ‘logreg’ and ‘polyreg’ arguments in mice,
which correspond to logistic and multinomial logistic regression models, respectively [63]. We used the
packages’s default flat, improper priors; the priors are independent both across models and across param-
eters in these models. We modified the mice package to permit interaction terms and to enforce upper
and lower bounds on imputed values. Finally, we added internal checks to increase stability when near
singularities occur because of small sample sizes and collinearity. Imputing PANSS with the R package
pan implies a multivariate Gaussian distribution for the imputation model. The default priors for this
model are a flat improper prior for the fixed effects with Inverse-Wishart priors placed on the variance
components of the random effect and error terms. Sensitivity analyses can be used to assess the influence
of the prior distribution of the imputed data [64].
We first used mice to impute missing values in baseline variables, conditioning on the fully observed
baseline variables. Next, we used mice to impute the missing month 1 variables. Note that the missing
values of baseline variables in the conditioning set were filled in on the prior step with mice. To impute
missing values of the month 1 longitudinal outcome, R1 , we used pan to evaluate a BMEM for the
longitudinal outcome {R0,R1}. Draws from the posterior predictive distribution were used to impute
missing values of R1. The imputation with pan was performed as if there were no missing values in
the baseline and month 1 variables (except PANSS), as any missing values have been filled in. This
interweaving of mice and pan continued through all 18 months of CATIE until all missing values
were imputed. The Supporting information contains an artificial CATIE dataset with missing data and
corresponding R code implementing the imputation strategy described here.
5. Evaluating Clinical Antipsychotic Trial of Intervention and Effectiveness
treatment regimes
The goal of a SMART study is not just to compare one treatment with another but to compare entire
treatment regimes. As an illustration, we compare nine treatment regimes in terms of expected PANSS
score averaged over the quarterly PANSS scores collected during the CATIE study. Here, a treatment
regime is composed of two decision rules with the first decision rule dictating the first treatment, and the
second decision rule dictating a second treatment if the first treatment is discontinued. The regimes under
evaluation are given in Table II. Ziprasidone was approved by the US Food and Drug Administration
Table II. Estimated mean PANSS score over the 18 months of the Clinical Antipsychotic Trial of Intervention
and Effectiveness study for each of the nine treatment regimes and 95% confidence intervals.
Complete case Multiple imputation
Treatment regimes N Mean [95% CI] N Mean [95% CI]
Olanzapine, if nonresponder, then quetiapine 101 62.41 [60.05, 64.76] 186.3 65.99 [63.97, 68.00]
Olanzapine, if nonresponder, then risperidone 103 62.93 [60.46, 65.40] 186.8 66.08 [64.09, 68.07]
Olanzapine, if nonresponder
due to efficacy, then clozapine,
due to tolerance, then ziprasidone 109 63.21 [60.77, 65.65] 208.9 66.96 [65.04, 68.87]
Quetiapine, if nonresponder, then olanzapine 56 64.09 [60.66, 67.51] 145.4 68.86 [66.57, 71.15]
Quetiapine, if nonresponder, then risperidone 61 65.12 [62.01, 68.23] 146.1 69.32 [67.06, 71.57]
Quetiapine, if nonresponder
due to efficacy, then clozapine,
due to tolerance, then ziprasidone 64 65.75 [62.62, 68.89] 169.5 70.25 [67.92, 72.57]
Risperidone, if nonresponder, then olanzapine 83 66.67 [63.80, 69.54] 167.5 69.14 [66.92, 71.35]
Risperidone, if nonresponder, then quetiapine 79 65.49 [62.55, 68.44] 168.8 69.51 [67.31, 71.71]
Risperidone, if nonresponder
due to efficacy, then clozapine,
due to tolerance, then ziprasidone 83 66.32 [63.50, 69.14] 186.7 70.29 [68.08, 72.49]
The columns entitled complete case report the number of people (N) contributing information to estimating the mean
response for each regime, the estimated mean response, and corresponding 95% CI. The columns entitled multiple
imputation report the number of people (N) averaged over 25 imputations contributing information to estimating the
mean response for each regime as well as the estimated mean response and 95% CI.
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after CATIE enrollment had begun; consequently, Ziprasidone was not included as a first stage treatment
option for 571 CATIE participants; thus, Ziprasidone is not included as a first stage treatment option in
Table II. We also excluded Perphenazine because it cannot be taken by subjects with a prior diagnosis of
tardive dyskinesia, a movement disorder and side effect of first generation antipsychotics. The remaining
1014 CATIE participants were eligible to be included in our comparison of treatment regimes and were
randomized to one of olanzapine, risperidone, or quetiapine in the first CATIE treatment stage.
Recall that a CATIE participant, in consultation with their clinician, could decide at any visit that their
stage 1 treatment was no longer adequate and choose to enter the next treatment stage. We define this
choice to switch treatment a nonresponse to the first line of treatment. For nonresponders, we consider
three possible second line treatments: always assign olanzapine, quetiapine, or risperidone. According
to the CATIE protocol, a participant could not be re-randomized to the same treatment they received in
the first treatment stage; thus, each participant is only eligible for two of these three treatments. We also
consider a second stage decision rule that depends on the reason given for nonresponse: if nonresponse
is due to insufficient therapeutic effects treat with clozapine and if nonresponse is due to intolerable side
effects treat with ziprasidone. Note that in this example, we use treatment arm choice as a proxy for
reason for discontinuing treatment. In CATIE, reason for treatment discontinuation and treatment arm
was highly (but not perfectly) correlated.
Our analysis employs methods described in [65, 66]. In particular, we used weighted regression to
estimate the mean response and corresponding confidence intervals (CIs) for each regime under consid-
eration (the weights are used to adjust for unequal randomization probabilities). Individuals who remain
on their stage 1 treatment for the full 18 months are replicated to contribute information to all treat-
ment regimes beginning with that treatment. The sandwich estimator for standard errors accounts for the
weights and replicated observations [65–67].
Table II reports estimated mean responses and 95% CIs based on 25 imputed datasets constructed
using the algorithm described in Section 4. The mean response is averaged over 25 imputations. Standard
corrections are applied to adjust CIs to accommodate uncertainty in the imputations [22, p. 86–87]. We
also report the average number of individuals over the 25 completed datasets that contribute information
to the estimated mean response of each regime. For comparison, we report the corresponding estimates
based on a complete case analysis limited to CATIE individuals for whom all baseline covariate informa-
tion was collected, who remained in the CATIE study through the full 18 month and for whom PANSS
was recorded at all quarterly scheduled visits(N = 321).
Note that the complete case estimates appear to be systematically lower and more variable than esti-
mates using imputation. The lower mean is partially explained by the fact that patients with favorable
responses had a higher propensity to remain in the study. This is the type of bias we aim to correct using
imputation. Using the 25 imputations, the estimated treatment regimes that first treat with olanzapine
all have the lowest expected PANSS scores. The previously published primary analysis also found that
olanzapine was the most effective first-line medication in the CATIE study [31].
6. Discussion
As more SMARTs are implemented, it becomes increasingly important to provide practical and reliable
methods for dealing with missing data. In this paper, we identified five key challenges to applying impu-
tation methods to SMARTs and proposed an imputation procedure to meet these challenges. We specified
a joint distribution over all variables by using time-ordered nested conditional models and used a BMEM
to induce smoothness in longitudinal variables. While we used the CATIE study as an illustration, the
issues we raised and addressed apply to SMARTs in general.
Dropout is a major source of missing data in all longitudinal studies, as it was in CATIE [23].
While strategies to minimize study dropout should be applied in the SMART setting, these strategies
cannot completely eliminate participant dropout. For this reason, developing new, and evaluating
existing, methods for accommodating missing data in SMARTs is an important area of research.
Multiple imputation is one of several approaches for addressing the problem of missing data in these
settings. Multiple imputation is a natural choice for CATIE because of the need to conduct a variety
of secondary analyses. In particular, we not only want to facilitate a variety of longitudinal analyses,
we also want to investigate the quality of several dynamic treatment regimes using different variables
for individualizing treatment and possibly different outcomes, as illustrated in Section 5. Two alternate
approaches to multiple imputation are inverse probability weighting and likelihood methods [22,68,69];
a comparison of multiple imputation to these methods is needed in the SMART setting.
Copyright © 2014 John Wiley & Sons, Ltd. Statist. Med. 2014, 33 4202–4214
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There are a number of interesting directions in which this work might be extended. While it is common
for data from a SMART to exhibit a (nearly) monotone missingness pattern, this need not always be the
case. When the missingness pattern is not monotone, imputation models for variables measured at time
t should utilize variables measured at subsequent times s > t. A principled approach to imputing data
for nonmonotone missing data in SMARTs is needed. A further issue is extending imputation models for
longitudinal covariates with nonnormal distributions and constructing data-driven diagnostics to indicate
when such extensions are needed. Additionally, multiple imputation relies on the untestable assumption
that the data are MAR. It is unclear how violations of the MAR assumption will impact the estimation of
dynamic treatment regimes using data collected from a SMART. Specifically, it is unclear if violations of
this assumption will differentially impact the results of different methods for managing missing data. In
addition to the diagnostics, which can be found in the Supporting information (web address), sensitivity
analyses [70] could be performed to evaluate the impact of any violations to the MAR assumption on a
particular analysis.
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